At a glance
- Cosyntropin (tetracosactide) is an FDA-approved drug, marketed as Cortrosyn, Cosyntropin (first approval: April 22, 1970).
- PubMed lists 1,992 publications mentioning it, including 128 randomized controlled trials and 212 animal-only studies.
- ClinicalTrials.gov lists 56 registered studies testing it (11 active).
- FDA's adverse event system (FAERS) holds 453 reports mentioning it; 407 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
| Application | Product | Status | First approval | Sponsor |
|---|---|---|---|---|
| NDA016750 | CORTROSYN | Approved, marketed | April 22, 1970 | AMPHASTAR PHARMS INC |
| NDA022028 | COSYNTROPIN | Approved, discontinued | February 21, 2008 | SANDOZ |
| ANDA090574 | COSYNTROPIN | Approved, discontinued | December 17, 2009 | PHARMOBEDIENT |
| ANDA202147 | COSYNTROPIN | Approved, marketed | June 29, 2012 | SANDOZ |
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Iatrogenic Cushing Syndrome With Glucocorticoid-Induced Adrenal Insufficiency Following Prolonged Topical Clobetasol Use in an Adolescent.
- Testosterone and DHEA-S Secreting Adrenal Cortical Adenoma in a Postmenopausal Woman: A Rare Functional Incidentaloma.
- Biological response stability of refrigerated cosacthen after opening and non-hormonal effects of ACTH stimulation testing in healthy dogs.
- Case Report: Tislelizumab-associated secondary adrenal insufficiency in a patient with lung squamous cell carcinoma.
- ACTH-independent hypercortisolism across the cardiometabolic spectrum.
- The utility of cosyntropin stimulation test in the assessment of adrenal function after unilateral adrenalectomy.
- Prevalence of Adrenal Insufficiency in Clinically Stable Adults Living with HIV Attending Outpatient Clinics in Malaysia.
- Comparison of Salivary Cortisol, Cortisone, and Dexamethasone with Serum Measurements Across Dynamic Adrenal Testing.
- A randomized phase 2 placebo-controlled trial of clobetasol solution for oral chronic graft-versus-host disease therapy.
- Glucocorticoid-induced adrenal insufficiency from a supplement containing undisclosed dexamethasone.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 56
- Active
- 11
- With posted results
- 8
Conditions studied
Show 40 more studies
All 56 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 453
- Serious
- 407
- With death outcome
- 55
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
FDA prescribing information
Official US prescribing information. Dosing sections are intentionally not shown.
Source: DailyMed / openFDA
Change history
No changes since monitoring began on October 30, 2026.